← Leaderboards
Scott H Kaufmann
Mayo Clinic Rochester
$29,002,745
Attributed
$33,577,630
Total exposure
23
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$59,326,322 · 24
By mechanism
P50$33,799,868 · 9
R01$17,812,384 · 10
T32$7,440,816 · 3
P30$273,254 · 2
Top collaborators
- Kendall H. Lee5 shared
- Harry Long5 shared
- Lisa A. Schimmenti5 shared
- Zhenkun Lou2 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Tait D Shanafelt$9,008,119
Others in their field
Top investigators on “Clinic”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,108,147,906
- Leonard Freedman · Leidos Biomedical Research, Inc.$978,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$798,941,641
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$639,436,363
- Barton F Haynes · Duke University$546,907,423
Research focus
ClinicDesignInsightMalignant Neoplasm Of OvaryResponseFundingCellsMalignant NeoplasmsBaseOvarianPathway InteractionsCessation Of LifeClinical TrialsResistanceTumorSamplingMediatingProgramsInhibitor/AntagonistAffectResearch PersonnelIn VitroCytotoxicityDna Damage
Grant awards (123)
Mayo Clinic Ovarian Cancer SPORE$2,093,975
P50 · FY2025 · CA · contact PI
MSTP at Mayo Clinic Rochester$1,165,901
T32 · FY2025 · GM
Therapy of PARP inhibitor-associated myeloid neoplasms in ovarian cancer patients$466,152
R01 · FY2025 · CA · contact PI
Cause and therapeutic impact of DNA-protein crosslink repair defect in myeloid leukemias$363,713
R01 · FY2025 · CA · contact PI
Project 2: Next Generation TOP1 Inhibition for the Treatment of Ovarian Cancer$252,226
P50 · FY2025 · CA · contact PI
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancer$210,627
P50 · FY2025 · CA · contact PI
Novel Therapeutics and Therapeutic Modalities Research Program$133,372
P30 · FY2025 · CA · contact PI
Administration Core$126,697
P50 · FY2025 · CA · contact PI
Mayo Clinic Ovarian Cancer SPORE$1,818,053
P50 · FY2024 · CA · contact PI
MSTP at Mayo Clinic Rochester$1,198,718
T32 · FY2024 · GM
Therapy of PARP inhibitor-associated myeloid neoplasms in ovarian cancer patients$467,492
R01 · FY2024 · CA · contact PI
BAK Autoactivation in Hematological Malignancies$345,528
R01 · FY2024 · CA · contact PI
Cause and therapeutic impact of DNA-protein crosslink repair defect in myeloid leukemias$345,528
R01 · FY2024 · CA · contact PI
Project 2: Next Generation TOP1 Inhibition for the Treatment of Ovarian Cancer$242,263
P50 · FY2024 · CA · contact PI
Administration Core$201,750
P50 · FY2024 · CA · contact PI
Next Generation TOP1 Inhibition for the Treatment of Uterine Serous Carcinoma$201,750
P50 · FY2024 · CA · contact PI
Administration Core$115,348
P50 · FY2024 · CA · contact PI
Experimental Therapeutics Program$41,637
P30 · FY2024 · CA · contact PI
Mayo Clinic Ovarian Cancer SPORE$1,752,990
P50 · FY2023 · CA · contact PI
MSTP at Mayo Clinic Rochester$1,161,070
T32 · FY2023 · GM
BAK Autoactivation in Hematological Malignancies$356,438
R01 · FY2023 · CA · contact PI
Cause and therapeutic impact of DNA-protein crosslink repair defect in myeloid leukemias$356,438
R01 · FY2023 · CA · contact PI
Project 2: Next Generation TOP1 Inhibition for the Treatment of Ovarian Cancer$266,173
P50 · FY2023 · CA · contact PI
Administration Core$129,550
P50 · FY2023 · CA · contact PI
Experimental Therapeutics Program$98,245
P30 · FY2023 · CA · contact PI
Mayo Clinic Ovarian Cancer SPORE$1,749,801
P50 · FY2022 · CA · contact PI
Medical Scientist Training Program at Mayo Clinic$570,362
T32 · FY2022 · GM
Cause and therapeutic impact of DNA-protein crosslink repair defect in myeloid leukemias$356,438
R01 · FY2022 · CA · contact PI
BAK Autoactivation in Hematological Malignancies$356,438
R01 · FY2022 · CA · contact PI
Project 2: Next Generation TOP1 Inhibition for the Treatment of Ovarian Cancer$261,552
P50 · FY2022 · CA · contact PI
Administration Core$127,300
P50 · FY2022 · CA · contact PI
Mayo Clinic Ovarian Cancer SPORE$1,762,703
P50 · FY2021 · CA · contact PI
Medical Scientist Training Program at Mayo Clinic$645,155
T32 · FY2021 · GM
Cause and therapeutic impact of DNA-protein crosslink repair defect in myeloid leukemias$363,713
R01 · FY2021 · CA · contact PI
BAK Autoactivation in Hematological Malignancies$359,133
R01 · FY2021 · CA · contact PI
Project 2: Next Generation TOP1 Inhibition for the Treatment of Ovarian Cancer$262,127
P50 · FY2021 · CA · contact PI
Administration Core$132,270
P50 · FY2021 · CA · contact PI
Medical Scientist Training Program at Mayo Clinic$638,467
T32 · FY2020 · GM
Deubiquitinases in regulation of BRCA1 pathway$363,713
R01 · FY2020 · CA
BAK Autoactivation in Hematological Malignancies$359,133
R01 · FY2020 · CA · contact PI
Mayo Clinic Ovarian Cancer SPORE$2,139,000
P50 · FY2019 · CA · contact PI
Medical Scientist Training Program at Mayo Clinic$526,613
T32 · FY2019 · GM
Regulation of Death Ligand-Induced Killing$361,829
R01 · FY2019 · CA · contact PI
Mechanisms of PARP Inhibitor Resistance in Ovarian Cancer$356,033
R01 · FY2019 · CA · contact PI
Deubiquitinases in regulation of BRCA1 pathway$352,801
R01 · FY2019 · CA
Project 1 - PARP Project$222,109
P50 · FY2019 · CA · contact PI
Administrative Core$106,665
P50 · FY2019 · CA · contact PI
Career Enhancement Program$75,973
P50 · FY2019 · CA · contact PI
Mayo Clinic Ovarian Cancer SPORE$2,300,000
P50 · FY2018 · CA · contact PI
Administrative Core$577,791
P50 · FY2018 · CA · contact PI
Regulation of Death Ligand-Induced Killing$373,020
R01 · FY2018 · CA · contact PI
Mechanisms of PARP Inhibitor Resistance in Ovarian Cancer$372,824
R01 · FY2018 · CA · contact PI
Medical Scientist Training Program at Mayo Clinic$364,909
T32 · FY2018 · GM
Project 1 - PARP Project$188,026
P50 · FY2018 · CA · contact PI
Career Enhancement Program$93,569
P50 · FY2018 · CA · contact PI
Mayo Clinic Ovarian Cancer SPORE$2,300,000
P50 · FY2017 · CA · contact PI
Administrative Core$575,779
P50 · FY2017 · CA · contact PI
Mechanisms of PARP Inhibitor Resistance in Ovarian Cancer$382,326
R01 · FY2017 · CA · contact PI
Regulation of Death Ligand-Induced Killing$373,020
R01 · FY2017 · CA · contact PI
Medical Scientist Training Program at Mayo Clinic$228,053
T32 · FY2017 · GM
Project 1 - PARP Project$188,670
P50 · FY2017 · CA · contact PI
Career Enhancement Program$88,770
P50 · FY2017 · CA · contact PI
Mayo Clinic Ovarian Cancer SPORE$2,162,000
P50 · FY2016 · CA · contact PI
Administrative Core$527,228
P50 · FY2016 · CA · contact PI
Mechanisms of PARP Inhibitor Resistance in Ovarian Cancer$403,926
R01 · FY2016 · CA · contact PI
Regulation of Death Ligand-Induced Killing$373,020
R01 · FY2016 · CA · contact PI
Anticancer drug-induced BH3-only protein.Bak interactions$329,925
R01 · FY2016 · CA · contact PI
Medical Scientist Training Program at Mayo Clinic$280,536
T32 · FY2016 · GM
Project 1 - PARP Project$187,355
P50 · FY2016 · CA · contact PI
Mayo Clinic Ovarian Cancer SPORE$2,184,999
P50 · FY2015 · CA · contact PI
Administrative Core$587,017
P50 · FY2015 · CA · contact PI
Mechanisms of PARP Inhibitor Resistance in Ovarian Cancer$403,288
R01 · FY2015 · CA · contact PI
Regulation of Death Ligand-Induced Killing$373,020
R01 · FY2015 · CA · contact PI
Anticancer drug-induced BH3-only protein.Bak interactions$321,459
R01 · FY2015 · CA · contact PI
Project 1 - PARP Project$173,132
P50 · FY2015 · CA · contact PI
Mayo Clinic SPORE in Ovarian Cancer$622,294
P50 · FY2014 · CA · contact PI
Anticancer drug-induced BH3-only protein.Bak interactions$311,815
R01 · FY2014 · CA · contact PI
Mayo Clinic SPORE in Ovarian Cancer$2,150,500
P50 · FY2013 · CA · contact PI
Poisoning of PARP and Topoisomerase I to Treat Ovarian Cancer$304,054
P50 · FY2013 · CA · contact PI
Anticancer drug-induced BH3-only protein.Bak interactions$302,812
R01 · FY2013 · CA · contact PI
Developmental Research Program$148,656
P50 · FY2013 · CA · contact PI
Mayo Clinic SPORE in Ovarian Cancer$2,300,000
P50 · FY2012 · CA · contact PI
Poisoning of PARP and Topoisomerase I to Treat Ovarian Cancer$350,594
P50 · FY2012 · CA · contact PI
Anticancer drug-induced BH3-only protein.Bak interactions$332,564
R01 · FY2012 · CA · contact PI
Developmental Research Program$134,270
P50 · FY2012 · CA · contact PI
Poisoning of PARP and Topoisomerase I to Treat Ovarian Cancer$331,189
P50 · FY2011 · CA · contact PI
Developmental Research Program$130,351
P50 · FY2011 · CA · contact PI
Poisoning of PARP and Topoisomerase I to Treat Ovarian Cancer$351,800
P50 · FY2010 · CA · contact PI
Role of Proteases in Therapy-Induced Apoptosis$336,291
R01 · FY2010 · CA · contact PI
Topoisomerase I Inhibitors in Leukemia and Solid Tumors$221,813
R01 · FY2010 · CA · contact PI
Developmental Research Program$137,465
P50 · FY2010 · CA · contact PI
Role of Proteases in Therapy-Induced Apoptosis$329,695
R01 · FY2009 · CA · contact PI
Poisoning of PARP and Topoisomerase I to Treat Ovarian Cancer$315,836
P50 · FY2009 · CA · contact PI
Topoisomerase I Inhibitors in Leukemia and Solid Tumors$221,813
R01 · FY2009 · CA · contact PI
Developmental Research Program$137,621
P50 · FY2009 · CA · contact PI
Role of Proteases in Therapy-Induced Apoptosis$320,095
R01 · FY2008 · CA · contact PI
Topoisomerase I Inhibitors in Leukemia and Solid Tumors$221,813
R01 · FY2008 · CA · contact PI
Role of Proteases in Therapy-Induced Apoptosis$316,927
R01 · FY2007 · CA · contact PI
Preclinical Evaluation of Bcr/Abl-Directed Tyrphostins$273,076
R01 · FY2007 · CA · contact PI
Topoisomerase I Inhibitors in Leukemia and Solid Tumors$221,813
R01 · FY2007 · CA · contact PI
Role of Proteases in Therapy-Induced Apoptosis$328,884
R01 · FY2006 · CA · contact PI
Preclinical Evaluation of Bcr/Abl-Directed Tyrphostins$281,232
R01 · FY2006 · CA · contact PI
Topoisomerase I Inhibitors in Leukemia and Solid Tumors$228,438
R01 · FY2006 · CA · contact PI
Role of Proteases in Chemotherapy Induced Apoptosis$340,987
R01 · FY2005 · CA
Preclinical Evaluation of Bcr/Abl-Directed Tyrphostins$289,188
R01 · FY2005 · CA
MULTIDISCIPLINARY TRAINING IN EXPERIMENTAL HEMATOLOGY$146,364
T32 · FY2005 · HL
Role of Proteases in Chemotherapy Induced Apoptosis$331,053
R01 · FY2004 · CA
Preclinical Evaluation of Bcr/Abl-Directed Tyrphostins$298,688
R01 · FY2004 · CA
Topoisomerase I Inhibitors in Leukemia and Solid Tumors$222,233
R01 · FY2004 · CA
Multidisciplinary Training in Experimental Hematology$176,810
T32 · FY2004 · HL
Role of Proteases in Chemotherapy Induced Apoptosis$321,407
R01 · FY2003 · CA
Topoisomerase I Inhibitors in Leukemia and Solid Tumors$222,233
R01 · FY2003 · CA
MULTIDISCIPLINARY TRAINING IN EXPERIMENTAL HEMATOLOGY$174,283
T32 · FY2003 · HL
Role of Proteases in Chemotherapy Induced Apoptosis$338,746
R01 · FY2002 · CA
PRECLINICAL EVALUATION OF BCR/ABL DIRECTED TYRPHOSTINS$222,233
R01 · FY2002 · CA
Topoisomerase I Inhibitors in Leukemia and Solid Tumors$222,233
R01 · FY2002 · CA
MULTIDISCIPLINARY TRAINING IN EXPERIMENTAL HEMATOLOGY$111,963
T32 · FY2002 · HL
PROTEASES AND CHEMOTHERAPY INDUCED APOPTOSIS$228,399
R01 · FY2001 · CA
Topoisomerase I Inhibitors in Leukemia and Solid Tumors$222,233
R01 · FY2001 · CA
PRECLINICAL EVALUATION OF BCR/ABL DIRECTED TYRPHOSTINS$222,233
R01 · FY2001 · CA
MULTIDISCIPLINARY TRAINING IN EXPERIMENTAL HEMATOLOGY$51,612
T32 · FY2001 · HL
PROTEASES AND CHEMOTHERAPY INDUCED APOPTOSIS$222,856
R01 · FY2000 · CA
PRECLINICAL EVALUATION OF BCR/ABL DIRECTED TYRPHOSTINS$222,233
R01 · FY2000 · CA